{"key":"semax","slug":"semax","name":"Semax","other_names":["Semax acetate","N-Acetyl Semax"],"kind":"single","area":{"slug":"cognitive","name":"Cognitive"},"classification":"Synthetic ACTH(4-10) analogue","standing":{"id":"approved","label":"Licensed medicine","rank":5},"summary":"A heptapeptide analogue of a fragment of ACTH. It is a registered medicine in Russia and is not licensed in the United States or the European Union.","cas_number":"80714-61-0","molecular_formula":"C37H51N9O10S","molecular_weight":"813.9 g/mol","components":[],"has_article":false,"pubmed":{"papers":210,"in_humans":49,"clinical_trials":4},"retired":false,"updated_at":"2026-11-18T00:17:24.691Z","url":"https://pepts.wiki/compounds/semax","article":null,"evidence":{"query":"(\"Semax\"[tiab])","fetched_at":"2026-11-16T23:06:49.667Z","counts":{"rcts":1,"human":49,"total":210,"reviews":11,"clinicalTrials":4},"years":[{"year":2012,"count":7},{"year":2013,"count":11},{"year":2014,"count":7},{"year":2015,"count":7},{"year":2016,"count":5},{"year":2017,"count":9},{"year":2018,"count":4},{"year":2019,"count":3},{"year":2020,"count":7},{"year":2021,"count":9},{"year":2022,"count":4},{"year":2023,"count":3},{"year":2024,"count":4},{"year":2025,"count":8},{"year":2026,"count":9}],"top":[{"doi":"10.17116/jnevro20181183261-68","url":"https://pubmed.ncbi.nlm.nih.gov/29798983/","kind":"trial","pmid":"29798983","year":2018,"title":"[The efficacy of semax in the tretament of patients at different stages of ischemic stroke]","venue":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","authors":"Gusev EI, Martynov MY, Kostenko EV, et al."},{"doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/11517472/","kind":"trial","pmid":"11517472","year":1997,"title":"[Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]","venue":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","authors":"Gusev EI, Skvortsova VI, Miasoedov NF, et al."},{"doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/10741256/","kind":"trial","pmid":"10741256","year":2000,"title":"[Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease]","venue":"Vestnik oftalmologii","authors":"Polunin GS, Nurieva SM, Baiandin DL, et al."},{"doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/18379501/","kind":"rct","pmid":"18379501","year":2007,"title":"[The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax]","venue":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","authors":"Serdiuk AV, Levitskiĭ GN, Miasoedov NF, et al."},{"doi":"10.1134/S001249662001007X","url":"https://pubmed.ncbi.nlm.nih.gov/32342318/","kind":"study","pmid":"32342318","year":2020,"title":"Functional Connectomic Approach to Studying Selank and Semax Effects","venue":"Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections","authors":"Panikratova YR, Lebedeva IS, Sokolov OY, et al."},{"doi":"10.5435/JAAOSGlobal-D-25-00236","url":"https://pubmed.ncbi.nlm.nih.gov/41490200/","kind":"review","pmid":"41490200","year":2026,"title":"Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions","venue":"Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews","authors":"Rahman OF, Lee SJ, Seeds WA"},{"doi":"10.1016/j.npep.2020.102114","url":"https://pubmed.ncbi.nlm.nih.gov/33418449/","kind":"study","pmid":"33418449","year":2021,"title":"Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats","venue":"Neuropeptides","authors":"Glazova NY, Manchenko DM, Volodina MA, et al."},{"doi":"10.1007/s00438-017-1297-1","url":"https://pubmed.ncbi.nlm.nih.gov/28255762/","kind":"study","pmid":"28255762","year":2017,"title":"Semax, an analog of ACTH((4-7)), regulates expression of immune response genes during ischemic brain injury in rats","venue":"Molecular genetics and genomics : MGG","authors":"Medvedeva EV, Dmitrieva VG, Limborska SA, et al."},{"doi":"10.1007/s10517-018-4234-3","url":"https://pubmed.ncbi.nlm.nih.gov/30225715/","kind":"study","pmid":"30225715","year":2018,"title":"Effects of Semax on the Default Mode Network of the Brain","venue":"Bulletin of experimental biology and medicine","authors":"Lebedeva IS, Panikratova YR, Sokolov OY, et al."},{"doi":"10.1111/bph.70122","url":"https://pubmed.ncbi.nlm.nih.gov/40692165/","kind":"study","pmid":"40692165","year":2025,"title":"Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice","venue":"British journal of pharmacology","authors":"Liu R, Chen Y, Huang H, et al."}]},"library_version":"183:2026-11-17T11:05:42.386Z","attribution":"Data from Pepts.wiki (https://pepts.wiki), CC BY 4.0. Link back to the compound's page.","notice":"We are not doctors, and nothing on Pepts.wiki is medical advice or a recommendation to use anything. The wiki sets out what studies measured, as clearly and evenly as it can, so you can make better-informed decisions. Always consult a medical professional before acting on anything you read here."}